

CHECKPOINT TRENDS LIMITED

Formerly known as Rubra Medicaments Limited

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | Website: www.rubramed.com

CIN: L74110MH1991PLC326598 | Tel: +91 9167469649

February 7, 2024

To,

BSE Limited,

P.J. Towers, Dalal Street,

Mumbai – 400 001

Scrip Code : 531099

Sub : Outcome of Board Meeting

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at its meeting held on Wednesday, February 7, 2024, inter alia, has considered and approved the Unaudited Standalone Financial Results along with Limited review report for the quarter ended December 31, 2023.

The meeting commenced at 02.00 P.M. and concluded at 3.30 P.M.

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

**For Checkpoint Trends Limited
Formerly known as Rubra Medicaments Limited**



**Abha Kapoor
Whole time Director & CFO
DIN – 02799429**

Checkpoint Trends Limited
(Formerly known as Rubra Medicaments Limited)

Statement of Standalone Unaudited Financial Results for the quarter ended December 31, 2023

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Year to date Figures for current period ended	Year to date Figures for previous period ended	Figures for the previous year ended
		31-Dec-2023	30-Sep-2023	31-Dec-2022	31-Dec-2023	31-Dec-2022	31-Mar-2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	17.00	29.00	21.02	66.00	108.02	116.02
II	Other Income	0.09	0.00	0.12	0.09	0.16	0.16
III	Total Income (I + II)	17.09	29.00	21.14	66.09	108.18	116.18
IV	Expenses:						
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	3.51	5.63	8.98	11.84	21.06	35.36
	Finance Costs	0.00	0.00	0.00	0.00	0.00	0.01
	Depreciation & amortisation expense	0.18	0.16	0.05	0.5	0.13	0.29
	Other Expenses	7.7	-2.60	11.98	27.64	83.71	88.59
	Total Expenses (IV)	11.39	3.19	21.01	39.98	104.90	124.25
V	Profit / (loss) before exceptional items and tax (III-IV)	5.70	25.81	0.13	26.11	3.28	-8.07
VI	Exceptional Items	0.00	0.00	0.09	0.00	0.09	0.00
VII	Profit / (loss) before tax (V-VI)	5.70	25.81	0.22	26.11	3.37	-8.07
VIII	Tax Expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.79	-0.22
	(2) Deferred tax	0.00	-0.06	0.00	-0.06	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	5.70	25.87	0.22	26.17	2.58	-7.85
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	5.70	25.87	0.22	26.17	2.58	-7.85
XIV	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	5.70	25.87	0.22	26.17	2.58	-7.85
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.1	0.47	0.01	0.48	0.05	0.00
	(2) Diluted	0.1	0.47	0.01	0.48	0.05	0.00
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic	0	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0	0.00	0.00	0.00	0.00	0.00
XVIII	Earnings per equity share (for discontinued & continuing operation):						
	(1) Basic	0.1	0.47	0.01	0.48	0.05	0.00
	(2) Diluted	0.1	0.47	0.01	0.48	0.05	0.00
	NOTES:						
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.						
2	The Segment - wise details are not applicable to the Company as the Company has only one segment.						
3	The result is provisional and unaudited and subject to change, regrouping and restatement.						

For Checkpoint Trends Limited
Formerly known as Rubra Medicaments Limited



Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

Place: Mumbai

Date:- February 7, 2024

L K AJMERA & ASSOCIATES

CHARTERED ACCOUNTANTS

Add : 206, Dimple Arcade, Thakur Complex, Kandivali East, Mumbai - 400101

Mail Id: calkajmera@lkajmera.com / lkajmera2013@gmail.com, Contact no- 9079256630

Independent Auditor's Review Report on Unaudited Quarterly Financial Results

To the Board of Directors of Checkpoint Trends Limited

1. We have reviewed the accompanying statement of unaudited financial results of Checkpoint Trends Limited ('the Company') for the quarter ended 31 December 2023 ('the Statement') being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For L K Ajmera & Associates

Chartered Accountants
Firm regn no. 137051W

Lalit Kumar Ajmera

Lalit Kumar Ajmera
Proprietor
Membership no 156116
ICAI UDIN : 24156116BKAIPG8025
Place Mumbai
Date: 07th Feb, 2024
Peer Review Certificate No - 014614

